FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1664326306> ?p ?o ?g. }

• W1664326306 endingPage "15624" @default.
• W1664326306 startingPage "15619" @default.
• W1664326306 abstract "Arachidonyl trifluoromethyl ketone (AACOCF3) is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2) (Street, I. P., Lin, H.-K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). AACOCF3 and a number of its structural analogues have been used to investigate the role of cPLA2 in the cellular generation of free arachidonic acid (AA) and in eicosanoid biosynthesis. AACOCF3 inhibited the release of AA from calcium ionophore-challenged U937 cells (IC50 = 8 microM, 2 x 10(6) cells ml-1) and from platelets (IC50 = 2 microM, 4 x 10(7) cells ml-1). Arachidonyl methyl ketone (AACOCH3) and AACH(OH)CF3, both of which are noninhibitory to the purified cPLA2, did not inhibit the production of AA in the ionophore-challenged cells. In addition to the release of AA, AACOCF3 also inhibited the production of 12-hydroxyeicosatetraenoic acid (12-HETE) and thromboxane B2, two of the major metabolites of AA produced by platelets. The inhibition of 12-HETE biosynthesis showed a dose dependence similar to that of AA release in ionophore-challenged platelets; however, when platelet 12-HETE production was stimulated with 10 microM AA to circumvent the PLA2-dependent step, AACOCF3 no longer inhibited the production of 12-HETE. In contrast, AACOCF3 blocked thromboxane B2 formation by both calcium ionophore- and AA-challenged platelets, indicating that the compound affects the cyclooxygenase pathway in addition to AA release. The crude cytosol and membrane fractions from platelets were assayed for calcium-dependent and calcium-independent PLA2 activities and for the susceptibility of each to inhibition by AACOCF3. At AACOCF3 concentrations as high as 10 mol %, only one of the observed PLA2 activities was inhibited by more than 25%. The AACOCF3-susceptible PLA2 (77% inhibition at 1.6 mol %) was found in the cytosolic platelet fraction and showed the functional characteristics of the cPLA2. These results suggest that the cPLA2 plays an important role in the generation of free AA for 12-HETE biosynthesis in platelets." @default.
• W1664326306 created "2016-06-24" @default.
• W1664326306 creator A5002319870 @default.
• W1664326306 creator A5012243268 @default.
• W1664326306 creator A5024644512 @default.
• W1664326306 creator A5027247101 @default.
• W1664326306 creator A5028459087 @default.
• W1664326306 creator A5058120869 @default.
• W1664326306 creator A5063518304 @default.
• W1664326306 creator A5066603239 @default.
• W1664326306 creator A5072727907 @default.
• W1664326306 creator A5085208574 @default.
• W1664326306 date "1994-06-01" @default.
• W1664326306 modified "2023-10-16" @default.
• W1664326306 title "Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets." @default.
• W1664326306 cites W1501606466 @default.
• W1664326306 cites W1511017475 @default.
• W1664326306 cites W1511192707 @default.
• W1664326306 cites W1538690208 @default.
• W1664326306 cites W1567170846 @default.
• W1664326306 cites W1641540149 @default.
• W1664326306 cites W1751643275 @default.
• W1664326306 cites W1775585066 @default.
• W1664326306 cites W1966871759 @default.
• W1664326306 cites W1983310448 @default.
• W1664326306 cites W1983478202 @default.
• W1664326306 cites W1984787065 @default.
• W1664326306 cites W1991982065 @default.
• W1664326306 cites W1996951958 @default.
• W1664326306 cites W2021022873 @default.
• W1664326306 cites W2022037486 @default.
• W1664326306 cites W2022073216 @default.
• W1664326306 cites W2030997003 @default.
• W1664326306 cites W2034277711 @default.
• W1664326306 cites W2047717260 @default.
• W1664326306 cites W2050832307 @default.
• W1664326306 cites W2051958752 @default.
• W1664326306 cites W2057345518 @default.
• W1664326306 cites W2067048966 @default.
• W1664326306 cites W2067986887 @default.
• W1664326306 cites W2069582126 @default.
• W1664326306 cites W2074260405 @default.
• W1664326306 cites W2083444173 @default.
• W1664326306 cites W2092580183 @default.
• W1664326306 cites W2093745776 @default.
• W1664326306 cites W2094053094 @default.
• W1664326306 cites W2146388445 @default.
• W1664326306 cites W2293695516 @default.
• W1664326306 cites W2415214386 @default.
• W1664326306 cites W54579200 @default.
• W1664326306 doi "https://doi.org/10.1016/s0021-9258(17)40726-5" @default.
• W1664326306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8195210" @default.
• W1664326306 hasPublicationYear "1994" @default.
• W1664326306 type Work @default.
• W1664326306 sameAs 1664326306 @default.
• W1664326306 citedByCount "243" @default.
• W1664326306 countsByYear W16643263062012 @default.
• W1664326306 countsByYear W16643263062013 @default.
• W1664326306 countsByYear W16643263062014 @default.
• W1664326306 countsByYear W16643263062015 @default.
• W1664326306 countsByYear W16643263062016 @default.
• W1664326306 countsByYear W16643263062017 @default.
• W1664326306 countsByYear W16643263062018 @default.
• W1664326306 countsByYear W16643263062019 @default.
• W1664326306 countsByYear W16643263062020 @default.
• W1664326306 countsByYear W16643263062021 @default.
• W1664326306 countsByYear W16643263062023 @default.
• W1664326306 crossrefType "journal-article" @default.
• W1664326306 hasAuthorship W1664326306A5002319870 @default.
• W1664326306 hasAuthorship W1664326306A5012243268 @default.
• W1664326306 hasAuthorship W1664326306A5024644512 @default.
• W1664326306 hasAuthorship W1664326306A5027247101 @default.
• W1664326306 hasAuthorship W1664326306A5028459087 @default.
• W1664326306 hasAuthorship W1664326306A5058120869 @default.
• W1664326306 hasAuthorship W1664326306A5063518304 @default.
• W1664326306 hasAuthorship W1664326306A5066603239 @default.
• W1664326306 hasAuthorship W1664326306A5072727907 @default.
• W1664326306 hasAuthorship W1664326306A5085208574 @default.
• W1664326306 hasBestOaLocation W16643263061 @default.
• W1664326306 hasConcept C126322002 @default.
• W1664326306 hasConcept C178790620 @default.
• W1664326306 hasConcept C181199279 @default.
• W1664326306 hasConcept C185592680 @default.
• W1664326306 hasConcept C2776551241 @default.
• W1664326306 hasConcept C2777738585 @default.
• W1664326306 hasConcept C2778078955 @default.
• W1664326306 hasConcept C2779014961 @default.
• W1664326306 hasConcept C2779630222 @default.
• W1664326306 hasConcept C519063684 @default.
• W1664326306 hasConcept C55493867 @default.
• W1664326306 hasConcept C71924100 @default.
• W1664326306 hasConcept C89560881 @default.
• W1664326306 hasConceptScore W1664326306C126322002 @default.
• W1664326306 hasConceptScore W1664326306C178790620 @default.
• W1664326306 hasConceptScore W1664326306C181199279 @default.
• W1664326306 hasConceptScore W1664326306C185592680 @default.
• W1664326306 hasConceptScore W1664326306C2776551241 @default.
• W1664326306 hasConceptScore W1664326306C2777738585 @default.

• next